Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Germany / NCT04393519
Recruiting Observational

Non-invasive Evaluation Program for TIPS and Follow Up Network 2 (NEPTUN2)

NCT04393519 · tracked via the Priya Life Science Germany tracker
Sponsor
University Hospital, Bonn
Phase
Observational
Started
2020-05-12
Last updated
2021-10-05

Condition(s) studied

Portal Hypertension

Investigational drug(s) / intervention(s)

TIPS procedure

TIPS procedure: Implantation of TIPS for portal hypertension

Study summary

Evaluation of non-invasive prognostic parameters in patients receiving transjugular intrahepatic portosystemic shunt (TIPS) for complications of portal hypertension. Patients are cared according to the local standardized follow up program. Clinical and laboratory data from standard patient care are evaluated for potential prognostic value.

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * Insertion of TIPS according to guidelines Exclusion Criteria: * Contraindication for TIPS

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University Hospital Bonn Bonn Germany Recruiting

More University Hospital, Bonn trials in Germany

Clinical-randomized Trial of the Effect of Rehabilitation Therapy Using Strength and Blood Flow Restriction Training on Muscular Fitness and Regeneration After Anterior Cruciate Ligament Reconstruction Recruiting
Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity Recruiting
Blood Flow Restriction Training in Acute Geriatric Rehabilitation Recruiting
Vascular Liver Disease Evaluation, Follow Up and Non-Invasive Diagnostics Program Recruiting
Immunophenotyping in Patients With Osteoporosis Recruiting

Other trials for the same condition

Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D) Active, not recruiting
Freiburg TIPS Registry Recruiting
The BD Liverty™ TIPS Stent Graft Study Active, not recruiting
Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease Recruiting
Cera™ Vascular Plug System Post-Market Clinical Follow-Up Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04393519 on ClinicalTrials.gov ↗ ← All trials in Germany